Fluoxetine in tricyclic refractory major depressive disorder.
Fluoxetine in tricyclic refractory major depressive disorder.
复制标题
氟西汀治疗三环难治性重度抑郁症。
DOI：
10.1016/0165-0327(90)90144-w
复制
发表时间：
1990
影响因子：
6.6
通讯作者：
D. Masica
中科院分区：
文献类型：
--
作者：
Charles M. Beasley;M. Sayler;Gregory E. Cunningham;Alan M. Weiss;D. Masica
Data regarding open-label treatment with fluoxetine following failure to respond to tricyclic antidepressants (TCAs) or intolerance of TCA side effects, suggest a response rate between 51.4% and 62.1%, depending on the definition of TCA refractoriness employed. Double-blind study of this issue would extend these findings. Fluoxetine is well tolerated in patients unable to tolerate TCAs. Within this population, more than 80% of patients unable to tolerate TCAs found fluoxetine acceptable. Fluoxetine, as an alternative to polypharmaceutical augmentation, may represent a logical choice as the next step in therapy for a patient who has initially been treated with a TCA and has proven refractory or intolerant.
抗抑郁药对正常人脑体外血清素 S1 和 S2 受体的拮抗作用。
影响因子：
5
作者：
Wander,TJ;Nelson,A;Okazaki,H;Richelson,E
通讯作者：
Richelson,E
DOI：
--
发表时间：
1984-07
期刊：
The Journal of pharmacology and experimental therapeutics
影响因子：
--
作者：
E. Richelson;A. Nelson
通讯作者：
E. Richelson;A. Nelson